Accelerating Drug Discovery with AI
Drug design remains a challenging endeavor due to the complexity of the involved design space. Artificial Intelligence provides a unique shot at the problem due to its capability of enabling efficient horizon exploration.
We are applying our AI capabilities in screening and de novo generation of antibodies and small molecule drugs against challenging targets such as intrinsically disordered pathogenic proteoforms involved in Parkinson’s disease.
Biophysics Meets Deep Learning
Deep Learning has revolutionized many fields but still remains in the nascent stages for drug design. Models like AlphaFold provide a strong foundation for the field but end-to-end solutions need to go far beyond. Hence, we develop novel architectures, built using biophysics principles at the core.
Our team consists of an ideal mix of members having strong experience in both the fields of biophysics and AI. We strongly believe in the importance of a multidisciplinary team for tackling the problem.